TrimRx vs MEDVi (2026): Two GLP-1 Pricing Models Compared
TrimRx and MEDVi are separate cash-pay telehealth programs. Compare the amount due, what period it covers, the follow-up charge and the current written terms. This page distinguishes new TrimRx public observations from historical MEDVi figures; it does not establish a current matched-term price winner.
Quick answer
The dated TrimRx public price explanation below distinguishes introductory offers from follow-up packages. The exact recurring billing period, calendar-month versus 4-week timing, required fees and all-in checkout charge were not verified. These public observations do not establish matched-term savings or a price at every dose. Confirm the medication, full charge, billing period and renewal terms in your own written quote. MEDVi figures elsewhere on this page are historical August 2026 observations. Confirm a current full quote from both companies before comparing.
Trimi publishes monthly and prepaid plans. Trimi's compounded semaglutide is $175 billed monthly and compounded tirzepatide is $235 billed monthly, with no multi-month commitment. Monthly plans renew automatically unless renewal is turned off; turning renewal off does not refund a term already paid for. Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically. The price is the same at every prescribed dose. Individual results vary.
Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. MEDVi price observations remain dated August 2026. TrimRx public price observations were checked October 25, 2026 (UTC); that price correction does not imply a new clinical review. Confirm current full quotes before enrolling.
Compare the charge and the commitment
Trimi's compounded semaglutide is $175 billed monthly and compounded tirzepatide is $235 billed monthly, with no multi-month commitment. Monthly plans renew automatically unless renewal is turned off; turning renewal off does not refund a term already paid for. Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically. Medication if prescribed, provider care and shipping are included; the price is the same at every prescribed dose.
What TrimRx and MEDVi each are
Definition
TrimRx (trimrx.com) is a cash-pay telehealth weight loss program offering compounded semaglutide and compounded tirzepatide, in oral and injectable formats, plus brand-name GLP-1 options, prescribed by licensed providers after an online health review. MEDVi (medvi.org) is a cash-pay telehealth platform providing compounded GLP-1 injections and dissolvable tablets through independent licensed providers in networks including OpenLoop Health, with prescriptions prepared by state-licensed pharmacies. Neither company is affiliated with the other, or with Trimi.
A quick disambiguation, because the names cause real confusion: TrimRx is not Trimi. They are separate, unaffiliated companies with different pricing, pharmacies, and provider networks , our TrimRx vs Trimi comparison covers that pairing in detail. This page compares TrimRx against MEDVi, the matchup people searching both brands actually want.
Both platforms are established players. MEDVi's own site claims more than 500,000 patients, and TrimRx was reviewed by U.S. News & World Report in June 2026, which credited it with fast onboarding, medication in about five to seven days for most patients, while noting slow customer service as its main weakness. Both companies describe legitimate clinical structures: an online intake, an asynchronous review by a licensed provider, and a prescription only when treatment is clinically appropriate. If you want the deeper single-provider write-ups, see is TrimRx legit and is MEDVi legit.
TrimRx vs MEDVi vs Trimi: side-by-side
TrimRx price observations were checked October 25, 2026 (UTC); its exact recurring period and all-in checkout total remain unverified. MEDVi figures remain dated August 2026 observations. The table does not establish matched-term savings.
TrimRx
Semaglutide: GLP-1: advertised from $179; Terms list $199 first month and $299 follow-up consultation package (checked October 25, 2026 (UTC)). Mira identifies this program as semaglutide; primary price passage does not name it. Recurring period and checkout total unverified.
Tirzepatide: GLP-1+GIP: advertised from $279; Terms list $349 first month and $399 follow-up consultation package (checked October 25, 2026 (UTC)). Terms name compounded tirzepatide. Recurring period and checkout total unverified.
Billing model: Primary introductory and follow-up package quotes checked October 25, 2026 (UTC); recurring period unverified
Extra fees: Required fees and all-in checkout total not verified
Commitment: Confirm the current written quote and covered term
MEDVi
Semaglutide: $179 advertised first month ($149 intro offers reported in Aug 2026 checks); refills listed at $299/mo in the same checks
Tirzepatide: Starting at $279 first month per 2026 checks; ongoing rates reported at $399–$499/mo depending on dose, confirm at intake
Billing model: Discounted first month, then the standard refill rate applies
Extra fees: No membership fee on compounded plans; branded routes use a separate membership structure
Commitment: Month-to-month, no contract
Trimi
Semaglutide: $175 billed monthly, or annual $1,188 upfront ($99/month equivalent)
Tirzepatide: $235 billed monthly, or annual $1,500 upfront ($125/month equivalent)
Billing model: Monthly billing or upfront payment for the full quarterly, 6-month or annual term; same price at every prescribed dose
Extra fees: None, no membership, consult, or dose-change fees
Commitment: Annual paid upfront for a 12-month commitment; 6-month and annual plans do not renew automatically
| Provider | Compounded semaglutide | Compounded tirzepatide | Billing model | Commitment |
|---|---|---|---|---|
| TrimRx | GLP-1: advertised from $179; Terms list $199 first month and $299 follow-up consultation package (checked October 25, 2026 (UTC)). Mira identifies this program as semaglutide; primary price passage does not name it. Recurring period and checkout total unverified. | GLP-1+GIP: advertised from $279; Terms list $349 first month and $399 follow-up consultation package (checked October 25, 2026 (UTC)). Terms name compounded tirzepatide. Recurring period and checkout total unverified. | Primary introductory and follow-up package quotes checked October 25, 2026 (UTC); recurring period unverified | Confirm the current written quote and covered term |
| MEDVi | $179 advertised first month ($149 intro offers reported in Aug 2026 checks); refills listed at $299/mo in the same checks | Starting at $279 first month per 2026 checks; ongoing rates reported at $399–$499/mo depending on dose, confirm at intake | Discounted first month, then the standard refill rate applies | Month-to-month, no contract |
| Trimi | $175 billed monthly, or annual $1,188 upfront ($99/month equivalent) | $235 billed monthly, or annual $1,500 upfront ($125/month equivalent) | Monthly billing or upfront payment for the full quarterly, 6-month or annual term; same price at every prescribed dose | Annual paid upfront for a 12-month commitment; 6-month and annual plans do not renew automatically |
Neither TrimRx nor MEDVi advertises a separate membership fee on compounded plans; MEDVi's brand-name routes use a separate membership-plus-medication structure. All three programs require a prescription from a licensed provider, and pricing at every provider only matters if a provider determines treatment is appropriate for you.
TrimRx's advertised starts and follow-up package quotes
Homepage starting offers, checked October 25, 2026 (UTC); Terms and conditions, checked October 25, 2026 (UTC); TrimRx review, October 1, 2026, secondary medicine mapping
TrimRx's homepage, checked October 25, 2026 (UTC), advertises GLP-1 from $179 and GLP-1+GIP from $279. Those starting offers are separate from its Terms prices. TrimRx's Terms, checked October 25, 2026 (UTC), list GLP-1 at $199 for the first month and $299 for a follow-up consultation package, and GLP-1+GIP at $349 for the first month and $399 for a follow-up consultation package. Mira's October 1, 2026 review identifies the GLP-1 program as semaglutide and GLP-1+GIP as tirzepatide. That medicine mapping is attributed secondary reporting; the primary GLP-1 price passage does not name semaglutide. The exact recurring billing period, calendar-month versus 4-week timing, required fees and all-in checkout charge were not verified. These public observations do not establish matched-term savings or a price at every dose. Confirm the medication, full charge, billing period and renewal terms in your own written quote.
Read the full covered term, amount due and refund conditions in the current written offer before prepaying. An introductory amount or a follow-up package quote alone does not establish your all-in ongoing cost.
Two more things worth knowing. First, TrimRx displays a LegitScript seal on its site, a meaningful verification signal in this category, and one you can confirm directly through LegitScript's checker. Second, TrimRx does not name its partner compounding pharmacy on its public pages, so ask which state-licensed pharmacy will prepare your prescription before you pay. Our TrimRx review and TrimRx cost guide cover the program in more depth.
MEDVi's model: a discounted first month, then the refill rate
MEDVi prices the opposite way. Instead of asking for months upfront, it discounts month one: compounded semaglutide injections start at $179 for the first month on MEDVi's own landing page in our August 2026 check, with $149 introductory offers reported by third-party reviews the same month, with no contract and free shipping. After the first month, 2026 pricing checks consistently list semaglutide refills at $299/month, a rate they describe as locked rather than rising with dose. The same checks put tirzepatide injections at $279 for the first month with ongoing rates reported at $399–$499/month depending on dose, and dissolvable GLP-1 tablets at $249. MEDVi's own pages carry the model's outline, a discounted start, no membership or hidden fees, and a money-back guarantee, but per-medication refill rates were not published on the public pages we checked, so confirm your exact rate before paying.
The refill rate, not the first-month rate, is the number to compare, because GLP-1 treatment is long-term: at listed rates, a first year of MEDVi semaglutide runs roughly $3,400–$3,470 ($149 or $179 plus eleven refills at $299), and third-party checks note MEDVi renews on 28-day cycles rather than calendar months, so a full year can include a thirteenth cycle. To MEDVi's credit, its structure is clean about what it excludes: compounded plans advertise no membership or hidden fees, the plan price covers the provider review, treatment plan, medication, and shipping, and HSA/FSA payment is accepted. Prescriptions are issued only after a consultation with an independent licensed provider, MEDVi works with provider networks including OpenLoop Health, and its pages state plainly that compounded medications are prepared by state-licensed pharmacies and are not FDA-approved.
MEDVi is month-to-month with no contract, which makes it the lower-risk way to start, and the more expensive way to continue. For the deeper breakdowns, see our MEDVi cost guide and MEDVi alternatives pages.
The third option: Trimi's flat annual pricing
Trimi's compounded semaglutide is $175 billed monthly and compounded tirzepatide is $235 billed monthly, with no multi-month commitment. Monthly plans renew automatically unless renewal is turned off; turning renewal off does not refund a term already paid for. Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically. The price is the same at every prescribed dose. Plans include medication if prescribed, provider access and free next-day-air shipping, once prescribed, with medication typically arriving within 36 hours.
How Trimi's structure compares on the points above:
- Same price at every prescribed dose; verify the full charge and plan commitment
- Monthly plans bill monthly; prepaid plans collect the full term upfront, including $1,188 semaglutide or $1,500 tirzepatide for the annual 12-month commitment
- Named 503A pharmacy: BelieveRx (Texas State Board of Pharmacy #35264) prepares each prescription
- Licensed provider care through the Arora Health 50-state network, included in the price
Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically. Compare the full upfront charge, commitment and included services with your own current quote rather than inferring a price winner from introductory rates. Compounded preparations are prepared per individual prescription and are not FDA-approved as drugs; a licensed provider decides whether treatment is appropriate.
For wider context on what the whole market charges, our compounded semaglutide cost guide and compounded tirzepatide cost guide break down the four billing models used across US telehealth, and if you are already on treatment with TrimRx or MEDVi, switching GLP-1 providers requires provider review and does not promise a gap-free transition.
What the medication does, wherever you get it
The clinical evidence behind these programs comes from trials of the FDA-approved products. In the STEP 1 trial, semaglutide 2.4 mg weekly produced an average 14.9% body-weight reduction over 68 weeks alongside lifestyle changes (Wilding et al., New England Journal of Medicine, 2021). In SURMOUNT-1, tirzepatide produced an average 20.9% reduction at the highest dose over 72 weeks (Jastreboff et al., NEJM, 2022). Compounded preparations have not been studied in trials of their own, and individual results vary.
That is also why the FDA's guidance matters when comparing providers: per the FDA, compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, and the agency's alert on unapproved GLP-1 drugs had logged 990 adverse event reports associated with compounded semaglutide as of May 31, 2026. The practical takeaway is not to avoid compounded treatment, it is to choose programs, like the three compared here, where a licensed provider prescribes and a verifiable state-licensed pharmacy prepares each prescription.
Five questions to ask TrimRx or MEDVi before you pay
- What is the refill price at your maintenance dose, not the first-month price?
- Is any multi-month plan billed upfront in full, and what is refunded if you stop early?
- Which state-licensed pharmacy prepares the prescription, and can the provider name it before you pay?
- Are provider visits, dose adjustments, and shipping included in the quoted number?
- What are the cancellation steps, in writing, before the first charge?
Which should you choose?
Compare the first charge and the follow-up quote
MEDVi figures on this page are historical August 2026 observations. Confirm its current amount due, covered period and follow-up charge directly before enrolling.
Read TrimRx's current written terms
The exact recurring billing period, calendar-month versus 4-week timing, required fees and all-in checkout charge were not verified. These public observations do not establish matched-term savings or a price at every dose. Confirm the medication, full charge, billing period and renewal terms in your own written quote.
Choose the Trimi commitment you intend to pay for
Trimi's compounded semaglutide is $175 billed monthly and compounded tirzepatide is $235 billed monthly, with no multi-month commitment. Monthly plans renew automatically unless renewal is turned off; turning renewal off does not refund a term already paid for. Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically.
Frequently asked questions
Are TrimRx and MEDVi the same company?
No. TrimRx and MEDVi are separate, unaffiliated telehealth companies. TrimRx runs a tiered-plan program for compounded GLP-1 medications with prepaid multi-month bundles, while MEDVi runs a discounted-first-month model with standard refill pricing afterward. TrimRx is also not affiliated with Trimi (trytrimi.com), despite the similar name, they are different companies with different pricing, pharmacies, and provider networks.
Which costs less, TrimRx or MEDVi?
The exact recurring billing period, calendar-month versus 4-week timing, required fees and all-in checkout charge were not verified. These public observations do not establish matched-term savings or a price at every dose. Confirm the medication, full charge, billing period and renewal terms in your own written quote. MEDVi figures elsewhere on this page are dated August 2026 observations. They are not a fresh quote. A matched-period comparison and current price winner are not established.
Does MEDVi charge a membership fee?
MEDVi's compounded GLP-1 plans advertise no membership or hidden fees, the plan price covers the provider review, treatment plan, medication, and shipping, per MEDVi's own pages as of August 2026. Its brand-name medication routes (such as Wegovy) use a separate membership-plus-medication structure. TrimRx likewise advertises no separate membership fee. Trimi's annual plan is $1,188 for semaglutide or $1,500 for tirzepatide upfront with a 12-month commitment, not a monthly charge, and no membership fee.
What medications do TrimRx and MEDVi offer?
Both programs center on compounded semaglutide and compounded tirzepatide prescribed by licensed providers after an online health review, and both also list brand-name GLP-1 options at higher prices. Both additionally market oral or dissolvable-tablet formats alongside weekly injections; the injectable route is the one used in the major clinical trials (STEP 1, SURMOUNT-1). Compounded preparations are prepared per individual prescription by state-licensed pharmacies and are not FDA-approved as drugs. Confirm the current medication lineup directly with each provider, as offerings change.
Are TrimRx and MEDVi legit?
Both operate as legitimate cash-pay telehealth platforms: licensed providers review an online intake, prescriptions are issued only when clinically appropriate, and medications are prepared by state-licensed pharmacies. TrimRx displays a LegitScript seal on its site, and MEDVi states that prescriptions are issued only after a consultation with an independent licensed provider through networks including OpenLoop Health. As with any GLP-1 program, verify the prescribing provider's licensure, ask which pharmacy prepares your prescription, and read the billing terms before paying.
How does Trimi compare to TrimRx and MEDVi?
Trimi's compounded semaglutide is $175 billed monthly and compounded tirzepatide is $235 billed monthly, with no multi-month commitment. Monthly plans renew automatically unless renewal is turned off; turning renewal off does not refund a term already paid for. Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically. The exact recurring billing period, calendar-month versus 4-week timing, required fees and all-in checkout charge were not verified. These public observations do not establish matched-term savings or a price at every dose. Confirm the medication, full charge, billing period and renewal terms in your own written quote. Trimi names BelieveRx (Texas State Board of Pharmacy #35264), a 503A pharmacy, and works with licensed providers through Arora Health. A provider decides whether to prescribe. Compounded medications are not FDA-approved; individual results vary.
Monthly billing or a prepaid annual commitment
Trimi's annual plans are $1,188 upfront for compounded semaglutide ($99/month equivalent) and $1,500 upfront for compounded tirzepatide ($125/month equivalent), with a 12-month commitment. The annual plans do not renew automatically.
Medication, licensed provider care, and free next-day-air shipping included, same price at every prescribed dose. The annual plan is a 12-month commitment with a 6-month money-back promise. A licensed provider determines eligibility; individual results vary.
Check your eligibilitySources
- MEDVi public pages (medvi.org, home.medvi.org, medvi.io): $179 starting price, no-membership-fee, money-back-guarantee, and patient-count claims; provider and pharmacy disclosures. Accessed August 31, 2026.
- Third-party MEDVi pricing checks (2026): $149 introductory offers, $299 semaglutide refill rate, $279 tirzepatide start, $249 tablet start, $399–$499 dose-tiered tirzepatide refills, 28-day renewal cycles. Independent pricing reviews accessed August 31, 2026.
- Homepage starting offers, checked October 25, 2026 (UTC)
- Terms and conditions, checked October 25, 2026 (UTC)
- TrimRx review, October 1, 2026, secondary medicine mapping
- Historical context: U.S. News & World Report TrimRx review (June 12, 2026), retained from the August 31, 2026 review.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216.
- US FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; adverse-event counts as of May 31, 2026. Accessed August 31, 2026.
Medical disclaimer: This article is for informational purposes only and is not medical advice. Semaglutide and tirzepatide are prescription GLP-1 medications. Common side effects include nausea, vomiting, diarrhea, and constipation; less common but serious risks include pancreatitis, gallbladder disease, and acute kidney injury (often from dehydration). Both medications carry a boxed warning for thyroid C-cell tumors observed in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Compounded semaglutide and tirzepatide are prepared per individual prescription by a state-licensed pharmacy and are not FDA-approved as drugs. TrimRx and MEDVi are competitor programs; this comparison presents their pricing and structures factually, verify current rates, terms, and offerings directly with each provider before making decisions. A licensed provider determines whether treatment is appropriate for you. Individual results vary.